reports
Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...
American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Rele...
American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, October 28, 2025. Senior management will hold a conference call for its third quarter 2025 earnings on Wednesday, October 29, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust,...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Louisiana-Pacific Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 September 2025 in which we reassessed the appropriateness of the ratings i...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...
American Assets Trust, Inc. Reports Second Quarter 2025 Financial Resu...
American Assets Trust, Inc. Reports Second Quarter 2025 Financial Results Net income available to common stockholders of $5.5 million and $48.0 million for the three and six months ended June 30, 2025, respectively, or $0.09 and $0.79 per diluted share, respectively. Funds from Operations ("FFO") excluding lease termination fees and litigation income of $0.51 and $1.03 per diluted share for the three and six months ended June 30, 2025, respectively, compared to $0.60 and $1.19 per diluted share for the same periods in 2024. Increased 2025 FFO per diluted share guidance to a range of ...
American Assets Trust, Inc. Announces Second Quarter 2025 Earnings Rel...
American Assets Trust, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its second quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, July 29, 2025. Senior management will hold a conference call for its second quarter 2025 earnings on Wednesday, July 30, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors secti...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board o...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biophar...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: “Dermatology: AA, HS, PSO”June 25, 2025, at 10am ET Live webcasts and replays, when a...
Avalo Reports First Quarter 2025 Financial Results and Recent Business...
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and...
Avalo Therapeutics to Participate in The Citizens Life Sciences Confer...
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at . The...
American Assets Trust, Inc. Reports First Quarter 2025 Financial Resul...
American Assets Trust, Inc. Reports First Quarter 2025 Financial Results Net income available to common stockholders of $42.5 million for the first quarter, or $0.70 per diluted share. Funds from Operations ("FFO") per diluted share excluding lease termination fees and litigation income decreased 10% year-over-year for the first quarter to $0.52 per diluted share. SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its first quarter ended March 31, 2025. First Quarter Highlights Net income availabl...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TXN TEXAS INSTRUMENTS INCORPORATED
TRN TRINITY INDUSTRIES INC.
THRM GENTHERM INCORPORATED
TER TERADYNE INC.
SLAB SILICON LABORATORIES INC.
SCL STEPAN COMPANY
ROG ROGERS CORPORATION
ROCK GIBRALTAR INDUSTRIES INC.
RBC REGAL BELOIT CORP
PCAR PACCAR INC
MGPI MGP INGREDIENTS INC.
LFUS LITTELFUSE INC.
LEN LENNAR CORPORATION CLASS A
KWR QUAKER CHEMICAL CORPORATION
IOSP INNOSPEC INC.
CGNX COGNEX CORPORATION
CCS CENTURY COMMUNITIES INC.
BZH BEAZER HOMES USA INC.
BCC BOISE CASCADE CO.
AOSL ALPHA & OMEGA SEMICONDUCTOR
AMPH AMPHASTAR PHARMACEUTICALS INC
ALB ALBEMARLE CORPORATION
MHK MOHAWK INDUSTRIES INC.
MG/CN MAGNA INTERNATIONAL INC.
BC BRUNSWICK CORPORATION
AMWD AMERICAN WOODMARK CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
MLHR HERMAN MILLER INC.
NX QUANEX BUILDING PRODUCTS CORPORATION
TNC TENNANT COMPANY
SITE SITEONE LANDSCAPE SUPPLY INC.
ICHR ICHOR HOLDINGS LTD.
APLS APELLIS PHARMACEUTICALS
YETI YETI HOLDINGS
HLIO HELIOS TECHNOLOGIES INC.
MBC_w MASTERBRAND INC
ZK ZEEKR INTELLIGENT TECHNOLOGY HOLDING LIMITED
TE ALUSSA ENERGY ACQUISITION CORP
American Assets Trust, Inc. Announces First Quarter 2025 Earnings Rele...
American Assets Trust, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its first quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, April 29, 2025. Senior management will hold a conference call for its first quarter 2025 earnings on Wednesday, April 30, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc...
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
American Assets Trust, Inc. Acquires Genesee Park Apartments in San Di...
American Assets Trust, Inc. Acquires Genesee Park Apartments in San Diego, California SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the successful acquisition of Genesee Park, a 192-unit apartment community located in San Diego, California. Genesee Park is currently approximately 93% leased with rental rates that the Company believes are significantly below prevailing market levels for the submarket. The acquisition presents a compelling opportunity to enhance the property’s value through strategic asset management in...
American Assets Trust, Inc. Announces Sale of Del Monte Shopping Cente...
American Assets Trust, Inc. Announces Sale of Del Monte Shopping Center in Monterey, California SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) announced today the sale of Del Monte Shopping Center, a premier retail destination in Monterey, California, for approximately $123.5 million, before closing prorations. "The sale of Del Monte Center is a strategic decision that allows us to focus on markets where we can achieve greater economies of scale and operational efficiencies while aligning with our long-term growth objectives. We are pr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.